Biodesix(us:BDSX)
1.57
+15.44%
Updated on 2024-12-22
Open:1.35
Close:1.57
High:1.61
Low:1.32
Pre Close:1.36
Volume:752510.00
Amount:1.13M
Turnover:0.52%
Shares:145.47M
MarketCap:228.38M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 59 | 53437002 | 36.82% | 18 | 14 | 21 |
| 2024-03-31 | 47 | 16084844 | 16.55% | 10 | 14 | 14 |
| 2023-12-31 | 41 | 16914372 | 17.58% | 5 | 13 | 14 |
| 2023-09-30 | 40 | 17123053 | 19.39% | 11 | 6 | 14 |
| 2023-06-30 | 34 | 16839459 | 21.42% | 4 | 10 | 10 |
| 2023-03-31 | 37 | 16664573 | 21.37% | 4 | 11 | 13 |
| 2022-12-31 | 39 | 16053271 | 20.68% | 12 | 8 | 13 |
| 2022-09-30 | 41 | 4754280 | 11.54% | 4 | 9 | 22 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Birchview Capital, Lp | 5193336 | 5.35% | 0 | |
| 2024-03-31 | Aigh Capital Management Llc | 3321085 | 3.42% | -1337861 | -28.72% |
| 2024-03-31 | Telemark Asset Management, Llc | 1326000 | 1.36% | 1250000 | 1644.74% |
| 2024-03-31 | Essex Investment Management Co Llc | 925614 | 0.95% | 12669 | 1.39% |
| 2024-03-31 | Wells Fargo & Company/Mn | 893203 | 0.92% | 9550 | 1.08% |
| 2024-03-31 | Vanguard Group Inc | 807928 | 0.83% | -3823 | -0.47% |
| 2024-03-31 | Opaleye Management Inc. | 534657 | 0.55% | 38157 | 7.69% |
| 2024-03-31 | Blackrock Inc. | 402908 | 0.41% | -1553 | -0.38% |
| 2024-03-31 | Geode Capital Management, Llc | 385145 | 0.40% | 28027 | 7.85% |
| 2024-03-31 | Legato Capital Management Llc | 334310 | 0.34% | 0 |
About
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.
Address:2970 Wilderness Place,Suite 100
Website:http://www.biodesix.com
Market Movers